Logo image of PMN

PROMIS NEUROSCIENCES INC (PMN) Stock Fundamental Analysis

NASDAQ:PMN - Nasdaq - CA74346M4065 - Common Stock - Currency: USD

0.815  -0.09 (-9.45%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PMN. PMN was compared to 571 industry peers in the Biotechnology industry. PMN has a great financial health rating, but its profitability evaluates not so good. PMN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PMN has reported negative net income.
In the past year PMN has reported a negative cash flow from operations.
In the past 5 years PMN always reported negative net income.
PMN had a negative operating cash flow in each of the past 5 years.
PMN Yearly Net Income VS EBIT VS OCF VS FCFPMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

With an excellent Return On Assets value of -2.30%, PMN belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
Looking at the Return On Equity, with a value of -7.75%, PMN belongs to the top of the industry, outperforming 91.09% of the companies in the same industry.
Industry RankSector Rank
ROA -2.3%
ROE -7.75%
ROIC N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PMN Yearly ROA, ROE, ROICPMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PMN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMN Yearly Profit, Operating, Gross MarginsPMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for PMN has been increased compared to 1 year ago.
Compared to 5 years ago, PMN has more shares outstanding
PMN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PMN Yearly Shares OutstandingPMN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
PMN Yearly Total Debt VS Total AssetsPMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

PMN has an Altman-Z score of 0.00. This is a bad value and indicates that PMN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PMN (0.00) is better than 63.64% of its industry peers.
There is no outstanding debt for PMN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0
ROIC/WACCN/A
WACCN/A
PMN Yearly LT Debt VS Equity VS FCFPMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M -15M

2.3 Liquidity

PMN has a Current Ratio of 9.30. This indicates that PMN is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 9.30, PMN is doing good in the industry, outperforming 77.36% of the companies in the same industry.
PMN has a Quick Ratio of 9.30. This indicates that PMN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PMN (9.30) is better than 77.36% of its industry peers.
Industry RankSector Rank
Current Ratio 9.3
Quick Ratio 9.3
PMN Yearly Current Assets VS Current LiabilitesPMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 89.84% over the past year.
EPS 1Y (TTM)89.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%321.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -7.20% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.81%
EPS Next 2Y19.16%
EPS Next 3Y20.62%
EPS Next 5Y-7.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMN Yearly Revenue VS EstimatesPMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
PMN Yearly EPS VS EstimatesPMN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PMN. In the last year negative earnings were reported.
Also next year PMN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PMN Price Earnings VS Forward Price EarningsPMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMN Per share dataPMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as PMN's earnings are expected to grow with 20.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.16%
EPS Next 3Y20.62%

More info and screens

0

5. Dividend

5.1 Amount

PMN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROMIS NEUROSCIENCES INC

NASDAQ:PMN (2/21/2025, 8:00:01 PM)

0.815

-0.09 (-9.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-14 2025-03-14/amc
Inst Owners29.84%
Inst Owner Change-80.9%
Ins Owners7.3%
Ins Owner Change10.02%
Market Cap26.64M
Analysts85.71
Price Target7.99 (880.37%)
Short Float %1.06%
Short Ratio4.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)351.06%
Min EPS beat(2)8.06%
Max EPS beat(2)694.06%
EPS beat(4)3
Avg EPS beat(4)159.79%
Min EPS beat(4)-68.9%
Max EPS beat(4)694.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.48%
EPS NQ rev (1m)12.5%
EPS NQ rev (3m)12.5%
EPS NY rev (1m)21.43%
EPS NY rev (3m)85.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.66
P/tB 3.66
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.3%
ROE -7.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.3
Quick Ratio 9.3
Altman-Z 0
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)6.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%321.05%
EPS Next Y94.81%
EPS Next 2Y19.16%
EPS Next 3Y20.62%
EPS Next 5Y-7.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-96.21%
EBIT Next 3Y-18.55%
EBIT Next 5Y33.13%
FCF growth 1Y-34.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.43%
OCF growth 3YN/A
OCF growth 5YN/A